211 related articles for article (PubMed ID: 12109906)
1. Structure-based approach for binding site identification on AmpC beta-lactamase.
Powers RA; Shoichet BK
J Med Chem; 2002 Jul; 45(15):3222-34. PubMed ID: 12109906
[TBL] [Abstract][Full Text] [Related]
2. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.
Powers RA; Blázquez J; Weston GS; Morosini MI; Baquero F; Shoichet BK
Protein Sci; 1999 Nov; 8(11):2330-7. PubMed ID: 10595535
[TBL] [Abstract][Full Text] [Related]
3. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
Weston GS; Blázquez J; Baquero F; Shoichet BK
J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design.
Usher KC; Blaszczak LC; Weston GS; Shoichet BK; Remington SJ
Biochemistry; 1998 Nov; 37(46):16082-92. PubMed ID: 9819201
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase.
Tondi D; Powers RA; Caselli E; Negri MC; Blázquez J; Costi MP; Shoichet BK
Chem Biol; 2001 Jun; 8(6):593-611. PubMed ID: 11410378
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii.
Powers RA; Swanson HC; Taracila MA; Florek NW; Romagnoli C; Caselli E; Prati F; Bonomo RA; Wallar BJ
Biochemistry; 2014 Dec; 53(48):7670-9. PubMed ID: 25380506
[TBL] [Abstract][Full Text] [Related]
7. Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases.
Caselli E; Powers RA; Blasczcak LC; Wu CY; Prati F; Shoichet BK
Chem Biol; 2001 Jan; 8(1):17-31. PubMed ID: 11182316
[TBL] [Abstract][Full Text] [Related]
8. The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution.
Chen Y; Minasov G; Roth TA; Prati F; Shoichet BK
J Am Chem Soc; 2006 Mar; 128(9):2970-6. PubMed ID: 16506777
[TBL] [Abstract][Full Text] [Related]
9. Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase.
Drawz SM; Taracila M; Caselli E; Prati F; Bonomo RA
Protein Sci; 2011 Jun; 20(6):941-58. PubMed ID: 21404358
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.
Concha NO; Janson CA; Rowling P; Pearson S; Cheever CA; Clarke BP; Lewis C; Galleni M; Frère JM; Payne DJ; Bateson JH; Abdel-Meguid SS
Biochemistry; 2000 Apr; 39(15):4288-98. PubMed ID: 10757977
[TBL] [Abstract][Full Text] [Related]
11. Nanomolar inhibitors of AmpC beta-lactamase.
Morandi F; Caselli E; Morandi S; Focia PJ; Blázquez J; Shoichet BK; Prati F
J Am Chem Soc; 2003 Jan; 125(3):685-95. PubMed ID: 12526668
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of AmpC beta-lactamase through a destabilizing interaction in the active site.
Trehan I; Beadle BM; Shoichet BK
Biochemistry; 2001 Jul; 40(27):7992-9. PubMed ID: 11434768
[TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors.
Morandi S; Morandi F; Caselli E; Shoichet BK; Prati F
Bioorg Med Chem; 2008 Feb; 16(3):1195-205. PubMed ID: 17997318
[TBL] [Abstract][Full Text] [Related]
14. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design.
Powers RA; Caselli E; Focia PJ; Prati F; Shoichet BK
Biochemistry; 2001 Aug; 40(31):9207-14. PubMed ID: 11478888
[TBL] [Abstract][Full Text] [Related]
15. Validation of the AmpC β-lactamase binding site and identification of inhibitors with novel scaffolds.
Chan FY; Neves MA; Sun N; Tsang MW; Leung YC; Chan TH; Abagyan R; Wong KY
J Chem Inf Model; 2012 May; 52(5):1367-75. PubMed ID: 22559726
[TBL] [Abstract][Full Text] [Related]
16. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase.
Powers RA; Morandi F; Shoichet BK
Structure; 2002 Jul; 10(7):1013-23. PubMed ID: 12121656
[TBL] [Abstract][Full Text] [Related]
17. Structure-based efforts to optimize a non-β-lactam inhibitor of AmpC β-lactamase.
Hendershot JM; Mishra UJ; Smart RP; Schroeder W; Powers RA
Bioorg Med Chem; 2014 Jul; 22(13):3351-9. PubMed ID: 24835785
[TBL] [Abstract][Full Text] [Related]
18. Thermodynamic cycle analysis and inhibitor design against beta-lactamase.
Roth TA; Minasov G; Morandi S; Prati F; Shoichet BK
Biochemistry; 2003 Dec; 42(49):14483-91. PubMed ID: 14661960
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of KPC-2 β-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226.
Ke W; Bethel CR; Papp-Wallace KM; Pagadala SR; Nottingham M; Fernandez D; Buynak JD; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2012 May; 56(5):2713-8. PubMed ID: 22330909
[TBL] [Abstract][Full Text] [Related]
20. Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase.
Werner JP; Mitchell JM; Taracila MA; Bonomo RA; Powers RA
Protein Sci; 2017 Mar; 26(3):515-526. PubMed ID: 27997706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
